Analysis Reveals Minimal Financial Impact of Drug Company Kickback Penalties
An analysis indicates that drugmakers penalized for kickbacks paid only 2.2% of their U.S. revenue from the implicated drugs over the past 25 years.
Recent analysis highlights that drug companies penalized for paying kickbacks to physicians have only incurred a minor financial impact, with penalties amounting to just 2.2% of their U.S. revenue from the specific drugs involved.
This assessment spans a significant timeframe of the past quarter century, suggesting a persistent trend in the pharmaceutical industry where financial penalties do not substantially deter revenue generation.
The findings raise questions about the effectiveness of regulatory measures in influencing corporate behavior within the healthcare sector, particularly regarding compliance and ethical practices.